641 related articles for article (PubMed ID: 29807101)
41. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus.
Foretz M; Guigas B; Viollet B
Nat Rev Endocrinol; 2019 Oct; 15(10):569-589. PubMed ID: 31439934
[TBL] [Abstract][Full Text] [Related]
42. [Insulin-sensitizing agents: metformin and thiazolidinedione derivatives].
Satoh J
Nihon Rinsho; 2003 Jul; 61(7):1224-9. PubMed ID: 12877089
[TBL] [Abstract][Full Text] [Related]
43. Metformin: New Preparations and Nonglycemic Benefits.
Fujita Y; Inagaki N
Curr Diab Rep; 2017 Jan; 17(1):5. PubMed ID: 28116648
[TBL] [Abstract][Full Text] [Related]
44. Anti-cancer Effects of Metformin: Recent Evidences for its Role in Prevention and Treatment of Cancer.
Kheirandish M; Mahboobi H; Yazdanparast M; Kamal W; Kamal MA
Curr Drug Metab; 2018; 19(9):793-797. PubMed ID: 29663879
[TBL] [Abstract][Full Text] [Related]
45. Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes.
Adamia N; Virsaladze D; Charkviani N; Skhirtladze M; Khutsishvili M
Georgian Med News; 2007 Apr; (145):52-5. PubMed ID: 17525501
[TBL] [Abstract][Full Text] [Related]
46. Metformin--the gold standard in type 2 diabetes: what does the evidence tell us?
Bosi E
Diabetes Obes Metab; 2009 May; 11 Suppl 2():3-8. PubMed ID: 19385978
[TBL] [Abstract][Full Text] [Related]
47. [Metformin - mechanisms of action and use for the treatment of type 2 diabetes mellitus].
Grzybowska M; Bober J; Olszewska M
Postepy Hig Med Dosw (Online); 2011 May; 65():277-85. PubMed ID: 21677353
[TBL] [Abstract][Full Text] [Related]
48. Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes.
Dutta S; Shah RB; Singhal S; Dutta SB; Bansal S; Sinha S; Haque M
Drug Des Devel Ther; 2023; 17():1907-1932. PubMed ID: 37397787
[TBL] [Abstract][Full Text] [Related]
49. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.
Dunn CJ; Peters DH
Drugs; 1995 May; 49(5):721-49. PubMed ID: 7601013
[TBL] [Abstract][Full Text] [Related]
50. [Anti-cancer activity of metformin: new perspectives for an old drug].
Beck E; Scheen AJ
Rev Med Suisse; 2010 Sep; 6(260):1601-7. PubMed ID: 20853715
[TBL] [Abstract][Full Text] [Related]
51. Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?
Shah RR
Drug Saf; 2017 Mar; 40(3):211-228. PubMed ID: 27981444
[TBL] [Abstract][Full Text] [Related]
52. Treatment of non-insulin-dependent diabetes mellitus with metformin.
Guthrie R
J Am Board Fam Pract; 1997; 10(3):213-21. PubMed ID: 9159660
[TBL] [Abstract][Full Text] [Related]
53. Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.
Crawley D; Chandra A; Loda M; Gillett C; Cathcart P; Challacombe B; Cook G; Cahill D; Santa Olalla A; Cahill F; George G; Rudman S; Van Hemelrijck M
BMC Cancer; 2017 Jul; 17(1):494. PubMed ID: 28732480
[TBL] [Abstract][Full Text] [Related]
54. Metformin: evidence-based versus rational pharmacotherapy.
Smits P; Tack CJ
Neth J Med; 2002 Jul; 60(6):228-30. PubMed ID: 12365465
[No Abstract] [Full Text] [Related]
55. [Metformin role in the treatment of type 2 diabetes in 2008].
Spada A; Philippe J
Rev Med Suisse; 2008 Jun; 4(160):1392-4, 1396-7. PubMed ID: 18630062
[TBL] [Abstract][Full Text] [Related]
56. New perspective for an old antidiabetic drug: metformin as anticancer agent.
Leone A; Di Gennaro E; Bruzzese F; Avallone A; Budillon A
Cancer Treat Res; 2014; 159():355-76. PubMed ID: 24114491
[TBL] [Abstract][Full Text] [Related]
57. Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?
Christodoulou MI; Scorilas A
Curr Med Chem; 2017; 24(1):14-56. PubMed ID: 27604091
[TBL] [Abstract][Full Text] [Related]
58. A New Role for an Old Drug: Metformin Targets MicroRNAs in Treating Diabetes and Cancer.
Zhou JY; Xu B; Li L
Drug Dev Res; 2015 Sep; 76(6):263-9. PubMed ID: 26936407
[TBL] [Abstract][Full Text] [Related]
59. Metformin targets multiple signaling pathways in cancer.
Lei Y; Yi Y; Liu Y; Liu X; Keller ET; Qian CN; Zhang J; Lu Y
Chin J Cancer; 2017 Jan; 36(1):17. PubMed ID: 28126011
[TBL] [Abstract][Full Text] [Related]
60. Effect of different glucose-lowering therapies on cancer incidence in type 2 diabetes: An observational population-based study.
Vicentini M; Ballotari P; Giorgi Rossi P; Venturelli F; Sacchettini C; Greci M; Mangone L; Pezzarossi A; Manicardi V
Diabetes Res Clin Pract; 2018 Sep; 143():398-408. PubMed ID: 29807100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
